Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cell-Impermeable Inhibitors Confirm That Intracellular Human Transglutaminase 2 Is Responsible for the Transglutaminase-Associated Cancer Phenotype.

International journal of molecular sciences - 8 Aug 2023

Gates Eric W J, Calvert Nicholas D, Cundy Nicholas J, Brugnoli Federica, Navals Pauline, Kirby Alexia, Bianchi Nicoletta, Adhikary Gautam, Shuhendler Adam J, Eckert Richard L, Keillor Jeffrey W

Abstract excerpt

Transglutaminase 2 (TG2) is a multifunctional enzyme primarily responsible for crosslinking proteins. Ubiquitously expressed in humans, TG2 can act either as a transamidase by crosslinking two substrates through formation of an Nε(ɣ-glutaminyl)lysine bond or as an intracellular G-protein. These discrete roles are tightly regulated by both allosteric and environmental stimuli and are associated with dramatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fluorescent Dyes
Share to Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Share to Protein Glutamine gamma Glutamyltransferase 2

Share to Transglutaminases

Source

Open in PubMed Open full text

Identifiers

PMID: 37628729
DOI: 10.3390/ijms241612546
PMCID: PMC10454375

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cell-Impermeable Inhibitors Confirm That Intracellular Human Transglutaminase 2 Is Responsible for the Transglutaminase-Associated Cancer Phenotype.PMID 37628729Read ↗

Transglutaminase 2 undergoes a large conformational change upon activation.Semantic proximity Read ↗

Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy targetSemantic proximity Read ↗

Discovery and Structure–Activity Relationship of Potent and Selective Covalent Inhibitors of Transglutaminase 2 for Huntington’s DiseaseSemantic proximity Read ↗

The Role of Transglutaminase 2 in Cancer: An UpdateSemantic proximity Read ↗

Tissue transglutaminase: from biological glue to cell survival cues.Semantic proximity Read ↗

Development of quantitative high-throughput screening assays to identify, validate, and optimize small-molecule stabilizers of misfolded β-glucocerebrosidase with therapeutic potential for Gaucher disease and Parkinson’s diseaseSemantic proximity Read ↗

Intracellular localization and conformational state of transglutaminase 2: implications for cell death.Semantic proximity Read ↗

Tissue transglutaminase: a new target to reverse cancer drug resistanceSemantic proximity Read ↗

Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53Semantic proximity Read ↗

Transglutaminase 2 strongly binds to an extracellular matrix component other than fibronectin via its second C-terminal beta-barrel domain.Semantic proximity Read ↗

Activity-regulating structural changes and autoantibody epitopes in transglutaminase 2 assessed by hydrogen/deuterium exchange.Semantic proximity Read ↗

The role of transglutaminase-2 and its substrates in human diseases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.